Rwanda: Akagera Medicines Gets Rwf11.5bn Grant to Advance TB Vaccine Trials
[New Times] Akagera Medicines, a biotechnology company majority-owned by Rwandans, has secured an additional $7.8 million (approximately Rwf11.5 billion) from the Gates Foundation to advance the development of a tuberculosis vaccine towards its first human clinical trial.
